Sarepta Therapeutics, Inc.

BIT:1SRPT Stock Report

Market Cap: €1.8b

Sarepta Therapeutics Management

Management criteria checks 2/4

Sarepta Therapeutics' CEO is Doug Ingram, appointed in Jun 2017, has a tenure of 9.08 years. total yearly compensation is $7.84M, comprised of 14.9% salary and 85.1% bonuses, including company stock and options. directly owns 0.37% of the company’s shares, worth €6.76M. The average tenure of the management team and the board of directors is 1 years and 10.1 years respectively.

Key information

Doug Ingram

Chief executive officer

US$7.8m

Total compensation

CEO salary percentage14.94%
CEO tenure9.1yrs
CEO ownership0.4%
Management average tenure1yr
Board average tenure10.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Doug Ingram's remuneration changed compared to Sarepta Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

US$65m

Dec 31 2025US$8mUS$1m

-US$713m

Sep 30 2025n/an/a

-US$272m

Jun 30 2025n/an/a

-US$58m

Mar 31 2025n/an/a

-US$248m

Dec 31 2024US$2mUS$847k

US$235m

Sep 30 2024n/an/a

US$122m

Jun 30 2024n/an/a

US$47m

Mar 31 2024n/an/a

US$17m

Dec 31 2023US$2mUS$800k

-US$536m

Sep 30 2023n/an/a

-US$691m

Jun 30 2023n/an/a

-US$908m

Mar 31 2023n/an/a

-US$1b

Dec 31 2022US$125mUS$740k

-US$703m

Sep 30 2022n/an/a

-US$716m

Jun 30 2022n/an/a

-US$507m

Mar 31 2022n/an/a

-US$357m

Dec 31 2021US$2mUS$730k

-US$419m

Sep 30 2021n/an/a

-US$486m

Jun 30 2021n/an/a

-US$634m

Mar 31 2021n/an/a

-US$704m

Dec 31 2020US$1mUS$669k

-US$554m

Sep 30 2020n/an/a

-US$601m

Jun 30 2020n/an/a

-US$530m

Mar 31 2020n/an/a

-US$656m

Dec 31 2019US$1mUS$650k

-US$715m

Compensation vs Market: Doug's total compensation ($USD7.84M) is above average for companies of similar size in the Italian market ($USD2.86M).

Compensation vs Earnings: Doug's compensation has been consistent with company performance over the past year.

CEO

Doug Ingram (63 yo)

9.1yrs
Tenure
US$7,840,666
Compensation

Mr. Douglas S. Ingram, J.D., Esq., also known as Doug, served as Independent Director of Arrowhead Pharmaceuticals, Inc. since February 06, 2025 until March 20, 2026. He has been Chief Executive Officer Sa...

Leadership Team

NamePositionTenureCompensationOwnership
Douglas Ingram
CEO & Director9.1yrsUS$7.84m0.37%
€ 6.8m
Ian Estepan
President & COO1yrUS$4.44m0.030%
€ 540.7k
Ryan Wong
Executive VP & CFO1yrUS$3.21m0.011%
€ 199.5k
Cristin Rothfuss
Executive VP1.7yrsUS$4.23mno data
Louise Rodino-Klapac
President of Research & Development and Technical Operations1yrUS$4.46m0.052%
€ 945.0k
Rachael Potter
Chief Scientific Officer1yrno datano data
Tamara Thornton
Director of Financeno datano datano data
Alison Nasisi
Executive VP & Chief People Officer4.8yrsno datano data
Diane Berry
Executive VP and Chief of Global Policy & Advocacy Officer6.8yrsno datano data
Patrick Moss
Executive VP & Chief Commercial Officer1yrno datano data
James Richardson
Executive VP & Chief Medical Officerless than a yearno datano data
Joseph Bratica
Controller & VP9.3yrsUS$911.89kno data
1.0yrs
Average Tenure
54yo
Average Age

Experienced Management: 1SRPT's management team is not considered experienced ( 1 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Douglas Ingram
CEO & Director9.1yrsUS$7.84m0.37%
€ 6.8m
M. Behrens Wilsey
Independent Chairwoman17.3yrsUS$603.92k0.20%
€ 3.6m
Hans Wigzell
Chairman of Corporate Strategy Board & Independent Non-Employee Director16.1yrsUS$562.47k0.024%
€ 436.9k
Richard Barry
Independent Director11.1yrsUS$577.28k3.05%
€ 55.7m
Beverly Davidson
Member of Strategic & Scientific Advisory Board10.9yrsno datano data
Deirdre Connelly
Independent Director1.8yrsUS$558.15k0.0032%
€ 57.6k
Joy Cavagnaro
Member of Scientific Advisory Board6.7yrsno datano data
Louis Kunkel
Member of Strategic & Scientific Advisory Board10.9yrsno datano data
Claude Nicaise
Independent Non-Employee Director11.1yrsUS$554.47k0.030%
€ 546.2k
Kenneth Fischbeck
Member of Strategic & Scientific Advisory Board9.3yrsno datano data
Carsten Bonnemann
Member of Scientific Advisory Board6.6yrsno datano data
Matthew Wood
Member of Strategic & Scientific Advisory Board9.3yrsno datano data
10.1yrs
Average Tenure
70yo
Average Age

Experienced Board: 1SRPT's board of directors are seasoned and experienced ( 10.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/08 00:36
End of Day Share Price 2026/07/08 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sarepta Therapeutics, Inc. is covered by 49 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Huidong WangBarclays
Eliana MerleBarclays